Clinical study of ghrelin administration on diabetic neuropathy

Clinical study of ghrelin administration on diabetic neuropathy - Clinical study of ghrelin on diabetic neuropathy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001707

Enrollment

Registered

2009-02-16

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes mellitus

Interventions

two weeks ghrelin administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes with diabetic neuropathy. HbA1c<9.1%

Exclusion criteria

Exclusion criteria: Insulin treatment. Severe liver or renal dysfunction. Severe heart diseases. Proliferative diabetic retinopathy. Medication with epalrestat, anti-eplepsy drugs, or mexiletine. Pregnant women.

Design outcomes

Primary

Measure	Time frame
Improvement of diabetic neuropathy. Changes of glucose metabolism and appetite.	—

Secondary

Measure	Time frame
Insulin secretion capacity.	—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

Miyazaki Medical College, University of Miyazaki Neurology, Respirology, Endocrinology and Metabolism

intron@med.miyazaki-u.ac.jp0985-85-9246

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026